Item Details
EQT’s Proposed QIAGEN Takeover Values the Transaction at Approximately €9.6 Billion
On 21 October, EQT’s acquisition vehicle announced a voluntary cash offer of €46.50 per QIAGEN share, valuing the Dutch-headquartered life-sciences company’s equity at approximately €9.6 billion. The proposed takeover remains subject to the offer process and applicable conditions; the reported figure is the proposed equity value, not a completed cash payment. Banks, investors and financial advisers can explore valuation modelling, portfolio-risk analysis and transaction forecasting, while HPC can support data-intensive financial workloads through a project-specific quotation.
Get in Touch
We’ll get back to you shortly.